SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar